drugset / Trial / NCT06319456
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
Timeline
- Start
- 2024-04-07
- Primary completion
- 2027-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | — | Oral |
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Comparator | Chlorambucil | Other / unclassified | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Fludarabine | Small molecule | — | — |
| Comparator | Rituximab | Monoclonal antibody | — | — |